Boston, MA and Providence, RI, Dec. 17, 2025 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (“PathMaker”), a clinical-stage neurotechnology company developing a breakthrough non-invasive approach for ...
Boomerang Medical, Inc., a women-led bioelectronic medicine company, today announced a $20 million Series B financing co-led by Arboretum Ventures and Hatteras Venture Partners. Proceeds will advance ...
Trial evaluates neuromodulation's potential role in ulcerative colitis, the most common form of IBD Boomerang Medical, Inc., a women-led bioelectronic medicine company, today announced a $20 million ...
The U.S. Food and Drug Administration has approved the SetPoint System, a neuroimmune modulation device for the treatment of adults living with moderate-to-severe rheumatoid arthritis (RA). The ...
THURSDAY, Aug. 7, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved the SetPoint System, a neuroimmune modulation device for the treatment of adults living with ...
Credit: SetPoint Medical. The SetPoint System consists of a neurostimulation device that is surgically placed under general anesthesia on the vagus nerve. In a phase 3 study, the SetPoint neuroimmune ...
In a phase 3 study, the SetPoint neuroimmune modulation device was found to be an effective treatment for patients with difficult-to-treat RA. The Food and Drug Administration (FDA) has approved the ...
Andrea Pezzella, MD, URPS, FACOG, stressed the need for offering patients comprehensive information on all available therapies. In a recent interview, Andrea Pezzella, MD, URPS, FACOG, of Southern ...
Pezzella said she believes Neuspera offers a "smart, integrated, sophisticated alternative" for treating overactive bladder symptoms. On June 18, 2025, the FDA granted clearance to Neuspera Medical’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback